ABL Diagnostics Selected by Évry Commercial Court to Acquire TEXCELL’s Operations

ABL Diagnostics Files Takeover Bid to Acquire IntegraGen

September 11, 2026

Healthcare Services

ABL Diagnostics (ABLD) announced it filed a takeover bid to acquire IntegraGen’s business operations and assets. The target is currently subject to judicial reorganization proceedings before the Commercial Court of Évry, and the bid remains subject to the court’s decision and selection as successful bidder.

Eurofins Agrees to Acquire SYNLAB’s Clinical Diagnostics Operations in Spain

October 28, 2024

Healthcare Services

Eurofins Scientific has reached an agreement with SYNLAB to acquire SYNLAB’s clinical diagnostics operations in Spain. The deal is subject to regulatory approvals and is expected to close in 2025.

Axol Bioscience Acquires Phenocell

October 21, 2024

Biotechnology

Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.